Sangamo Therapeutics Inc (SGMO)

$SGMO > Well La-T-Da , slow climb back UP ...

Enjoy the weekend >> M

$SGMO > Finally a little "sqeezee" going on ...

The PR https://www.globenewswire.com/news-release/2026/05/14/3294790/0/en/elevatebio-data-at-asgct-29th-annual-meeting-showcase-expanded-gene-editing-platform-and-services-spanning-new-modalities-ai-discovery-and-lnp-delivery.html

ElevateBio is now another. They will present at ASGCT as well.

The first set of data will be on how they applied an active learning framework to optimise novel large serine recombinases.

Recombinases can work (great) in bacteria, but disappoint in mammalian cells. So optimising in bacteria can be misleading, which is what ElevateBio is trying to fix.

Instead of generating a large number of variants, testing them (often in bacteria) and picking winners, they test a small set of variants in human cells, train an ML model, predict which new variants are most likely to improve performance and test only those. This is repeated.

If successful, it could reduce development time (dramatically), produce enzymes that are highly active and specific in human cells, and outperform (some of) the current methods used.

They explicitly say this can extend to transposases, R2 retrotransposases and other editors. That's big because it suggests this is not just a recombinase strategy - it is a platform for engineering other gene editing tools.

The second set of data will be on generating entirely new gene-editing enzymes that evolution never produced.

They collected ~370,000 deaminase sequences from a massive dataset (~10 billion proteins) and trained a protein language AI model to learn what makes an adenine deaminase function. This was then used as a model to generate ~2 million new protein sequences. These were filtered computationally (structure, folding, catalytic motifs) before hundreds of candidates were tested in mammalian cells. Ten functional enzymes (with <60% similarity to known proteins) were found.

This is a big deal as they created functional enzymes outside natural evolution. These are structurally valid, catalytically active, but largely novel in sequence space. They also proved the AI model works by generating, filtering, and validating in mammalian cells. The hit rate looks meaningful as well.

It allows them to move from engineering biology to designing biology. However, it is still early-stage. They showed activity, but not necessarily the efficiency needed for the clinic. Specificity and off-targets are unknown. The new enzymes may behave unpredictably. Delivery constraints remain. Scale-up will be challenging.

This approach could eventually produce smaller enzymes, improve specificity profiles, enable hard-to-target loci, as well as reduce IP constraints (tied to natural enzymes). The latter is one that is often overlooked but important commercially.

The third set of data is essentially describing a next-gen evolution of prime-like editing systems, but with a much broader and more industrialised discovery engine

What they are trying to change is some of the core limitations of current RT editors, including weak or suboptimal reverse transcriptases and targeting flexibility.

When it comes to the first, most current systems rely on a small set of engineered RTs (often viral-derived). Instead, billions of natural proteins were mined in order to identify new RT variants. These were then optimised for efficiency, fidelity, and compatibility with human cells.

As for the second, they pair these RTs with LEGs (Life Edit Genes), which are their proprietary CRISPR-like nucleases. So instead of being constrained by one targeting system (e.g., SpCas9), they have a diverse toolbox of targeting proteins and potentially better access to hard genomic sites.

In vitro, it resulted in >60% precise sequence replacement in primary hepatocytes. That's a strong result. Primary human hepatocytes are not trivial cells to edit. So this suggests high editing efficiency and good compatibility with therapeutically relevant cells. The important caveat is that it is in vitro and under optimised conditions. Historically, many editing systems drop significantly going from in vitro to in vivo, and dividing to non-dividing cells drops additionally. So real-world performance is still an open question.

Put together, they are building an end-to-end enzyme discovery plus optimisation engine, not just one modality.

Seamless will present data at ASGCT this month.

The first set of data is essentially describing how they are industrialising recombinase engineering. They started with massively diverse recombinase libraries from a pool of over 10,000 previously programmed libraries, and looking at useful traits across variants.

On top of this, undertaken alternative evolution with alternating selection. Instead of a single selection pressure, they are using switch selection schemes to refine both activity and specificity. Also, a dual screening strategy (both pooled screening and arrayed screening). The goal is to balance throughput and resolution.

In addition, adding ML in the loop (not just at the start), with protein language models to suggest new variants, which helps guide the next rounds of evolution.

Activity and specificity are further refined through orthogonal protein engineering (e.g., zinc finger fusions).

The key claim is ''target-matched recombinases within months.'' If true, that's huge. Because historically reprogramming recombinases has been slow and bespoke.

The second set of data is on the development of a suite of zinc finger fusions. They are layering domains into recombinases in two distinct ways.

The first is internal ZF fusions. In this, the ZF is inserted inside the recombinase structure. Activity becomes dependent on the recombinase recognition site and ZF binding nearby. Editing happens when both conditions are met.

The second is terminal ZF fusions. In this, the ZF is added to N- or C-terminus in order to help recruit the enzyme to DNA (like bringing the enzyme closer to its target and it works better). Doing so resulted in up to 10× activity increase in tyrosine recombinases and ~4× increase in large serine recombinases.

They didn't just add zinc fingers either. They mapped insertion tolerance with pentapeptide scanning mutagenesis (finding positions that don't break the protein), optimised linker design (length/rigidity/flexibility) and tested across classes, which suggests broad applicability.

$SGMO MMs back to doing what they do best >> SHORTING ...

SGMO delisted from the Nasdaq to the OTC. Stock was run from .13-ish to .217 on heavy volume, then dropped to ~.14. Volume 94.5 million.

https://otce.finra.org/otce/dailyList?viewType=Additions

https://otce.finra.org/otce/dailyList?viewType=Additions

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

Sangamo’s common stock to transition trading from The Nasdaq Capital Market to OTCQB Venture Market beginning May 5, 2026
2026-04-29 08:05 ET - News Release


RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq Capital Market to the OTCQB Venture Market on Tuesday, May 5, 2026. This transition follows the receipt by Sangamo of a notice from The Nasdaq Stock Market LLC indicating that Sangamo’s common stock will be delisted from the Nasdaq Capital Market due to non-compliance with Nasdaq’s minimum bid price requirement. Sangamo intends to request a hearing from Nasdaq to appeal the delisting determination. The hearing will not stay the suspension of trading of Sangamo’s common stock, and trading of Sangamo’s common stock on The Nasdaq Capital Market is expected to be suspended at the open of trading on May 5, 2026.

What an absolute train wreck!

Turns out recombinases aren't Profluent's first foray into gene editing. The company made a splash in 2024 when it used AI to make novel CRISPR proteins that don't exist in nature. https://www.nytimes.com/2024/04/22/technology/generative-ai-gene-editing-crispr.html https://www.biorxiv.org/content/10.1101/2024.04.22.590591v1.full

The CEO has insisted that Profluent is not a gene editing company. ''We don't consider ourselves a biotech company, or techbio company,'' he said. ''It's AI-first. That's the identity of the company.'' He also said the start-up's AI models can generate novel proteins broadly.

Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB marketApril 29, 2026 10:45 AM
IH Market News
Sangamo Therapeutics (NASDAQ:SGMO) announced a Nasdaq delisting and transition to the OTCQB Venture Market effective May 5, 2026, after failing to comply with the exchange’s minimum bid price requirement. The move is significant for investors as it changes where the stock trades and may affect liquidity and visibility.



Key Investor Takeaways




Nasdaq delisting will take effect May 5, with trading moving to OTCQB under the same ticker.



SGMO plans to appeal the delisting decision, but trading suspension will still proceed.



The company stated no expected material impact to business operations.



Sangamo is pursuing capital raises and potential business development deals.



OTC trading may impact liquidity and institutional participation for SGMO shares.




Press Release Overview



Sangamo said its common stock will be delisted from the Nasdaq Capital Market due to non-compliance with the minimum bid price requirement.Trading on Nasdaq is expected to be suspended at the open on May 5, 2026. The company intends to request a hearing to appeal the decision, although this will not delay the suspension.The stock has been approved to trade on the OTCQB Venture Market, operated by OTC Markets Group, and will continue trading under the ticker SGMO starting May 5.Sangamo said the transition is not expected to materially affect its operations. The company also noted it is exploring capital-raising opportunities and evaluating strategic options.



Why This Matters for Investors



The Nasdaq delisting could have implications for trading dynamics. Stocks moving to OTC markets often experience reduced liquidity, wider bid-ask spreads, and lower visibility among institutional investors.While the company stated operations remain unaffected, the shift in listing venue may influence investor perception and access to capital.At the same time, Sangamo’s ongoing efforts to secure financing and pursue business development deals may become more critical following the delisting.



What to Watch For Next




Outcome of Sangamo’s appeal process with Nasdaq



Execution of potential business development transactions



Any capital raises or financing announcements



Trading behavior and liquidity after the move to OTCQB




Conclusion



Sangamo’s Nasdaq delisting marks a key structural shift for the stock, even as the company continues to pursue strategic and financing initiatives. For investors, the focus now turns to execution and how the OTC transition impacts trading and sentiment.Sangamo Therapeutics stock price

Original: Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market

$SGMO: Added 200k here at $0.115 now.................

Gimme an $INHD kinda rebound if you could.

STOP set at $0.09


GO $SGMO

There are now three major camps:

1. Directed evolution
Seamless Therapeutics
Brink Therapeutics

Strengths:
grounded in experimental biology
proven path

Weakness:
slower scaling

2. AI-designed
Profluent
Basecamp

Strengths:
massive search space
potentially leapfrog biology

Weakness:
still depends on experimental validation

3. Hybrid engineering
Stylus Medicine

Strengths:
combines directed evolution, structural modelling, and ML/AI

Weakness:
complexity

Where does this leave Sangamo? Sangamo's MINT platform is based on Bxb1 recombinase engineering. It uses structural modelling, directed evolution and modular recombination.

But compared to this new landscape, the MINT platform looks to be slower, has narrower tech breadth, the funding is weak, and partners are declining.

Now with two partnerships the (uncomfortable) conclusion that Lilly - one of the most aggressive pharma companies right now - has validated recombinases, committed billions, but not chosen Sangamo. While that doesn't automatically mean Sangamo's tech is bad, it (strongly) suggests the market believes newer platforms may have higher ceiling and/or better execution potential.

A second deal https://www.fiercebiotech.com/biotech/lilly-pens-22b-pact-bezos-backed-profluent-work-recombinase-based-gene-editing

This deal is arguably even more telling than the first. It is clear Lilly is not just ''interested'' in recombinases. They are placing multiple bets across different technological platforms.

Profluent's angle is much closer to what Basecamp is doing, but could be more aggressive. Profluent uses foundation models for protein design and designs entirely new recombinases, not just tweaks. It aims for new target specificities, higher activity and potentially simpler architectures.

$SGMO > So , delisting to OCTBB next week then ...

SGMO.......................https://stockcharts.com/sc3/ui/?s=SGMO&p=w&b=5&g=0&id=p86431144783

Took a few this morning - A Lotto if you will

SGMO.............................https://stockcharts.com/sc3/ui/?s=SGMO&p=w&b=5&g=0&id=p86431144783

I found an interview yesterday in which two of the authors laid out a three-pillar engineering roadmap to turn INSTALL from a proof-of-concept into something clinically usable.

A primary focus will be identifying LNP formulations capable of efficiently co-delivering recombinase mRNA and INSTALL. Concurrently, refining the chemical modifications and sequence composition of the PIP oligo. Furthermore, continued engineering of recombinases. With multiplicative gains across all three areas that should bring efficiency into clinically relevant territory.

Most recombinase-based genome insertion systems require large double-stranded DNA (dsDNA) donors that are often long. But in mammalian cells large cytosolic dsDNA is a danger signal. Key innate immune sensors include pathways related to the cGAS-STING pathway. Different pathways are activated, including the interferon pathway and cells shut down translation or undergo apoptosis (programmed cell death). This means editing efficiency collapses.

This led to INSTALL (Integration through Nucleus-Synthesized Template Addition of Large Lengths), which avoids dsDNA-triggered innate toxicity and is compatible with recombinases https://www.nature.com/articles/s41586-026-10241-z

However, efficiency is still a huge problem, with less than 1% of mouse liver cells showing successful DNA integration. So INSTALL today is still an order of magnitude or more below where it needs to be. Even if LNP delivery works all the steps involved multiply inefficiency. As for recombinase activity, all the steps have failure probabilities.

While the study uses standard LNPs designed for delivering mRNA, the vehicle can be optimised. Also, if recombinases become at least 10-100x more active, which could be possible with groups using ML/AI models, INSTALL-type systems could suddenly cross therapeutic thresholds.

So INSTALL is a big advance but not a near-term clinical solution.

SGMO..................................https://stockcharts.com/sc3/ui/?s=SGMO&p=w&b=5&g=0&id=p86431144783

At ASGCT 2025, Stylus had an oral presentation on its engineering high-efficiency, high-specificity recombinases for in vivo engineering. The company reported engineering high-efficiency, high-specificity recombinases targeted to a novel safe harbour site in the human genome. The company's engineered recombinases act without the use of landing pads, protein fusions, or guide RNAs and possess a well-defined integration profile. These proprietary recombinases serve as the foundation of Stylus' in vivo genetic medicines platform, which features single-step insertion of multi-kb therapeutic payloads.

They also presented data on its in vivo CAR-T platform, which combines a proprietary recombinase that enables sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery.

Brink Therapeutics is yet another. The French company uses directed evolution. To speed things up, Brink also uses a technique called in vitro compartmentalisation, a way of running billions of enzyme reactions in parallel inside microscopic droplets. It's a miniaturised system that accelerates how quickly recombinases can be tested and optimised. By repeating these cycles, Brink can evolve recombinases that target specific genomic sites with high precision. The resulting data, on which enzymes work, and why, is being compiled into a proprietary library that will also feed into AI-driven design tools. This opens the door to eventually designing enzymes computationally before testing them in the lab, speeding up discovery even further.

The combination of in vitro directed evolution, metagenomic discovery and genAI platforms allows them to rapidly screen and capture activity data for billions of synthetic and natural recombinase sequences against diverse DNA target sequences, while continually learning from the results . The immediate goal is to validate five recombinases this year, demonstrating their ability to make precise and safe DNA edits in human cells. The company is also building a library of data that will underpin its AI-assisted enzyme design.

Stylus Medicine can join the list. Stylus' approach centres on an extensive, proprietary library of therapeutic-grade recombinases, optimised through computational design and machine learning for protein engineering.

There are at least two high-impact foundational studies that are directly relevant to Stylus Medicine's recombinase engineering platform and reflect the kind of scientific work that underpins their proprietary library and AI/ML-driven design strategy.

The first paper describes a new class of recombinases - called bridge recombinases - designed to perform large-scale programmable DNA rearrangements in human cells. These tools go well beyond simple insertions, with the potential to move or rearrange very large DNA segments. The bridge recombinases described were optimised for human cell function and can drive massive programmable DNA rearrangements (e.g., multi-megabase regions) with precision. It expands the landscape of recombinase-based editing beyond classic serine/tyrosine systems - showing that more complex rearrangements are possible, and not limited to small insertions or excisions https://www.science.org/doi/10.1126/science.adz0276

The second paper focuses on engineering large serine recombinases (LSRs) to achieve efficient and highly specific DNA insertion at defined human genomic loci without the need for pre-installed landing pads. It combines directed evolution, machine-learning-guided mutation combinations, dCas9 fusions, and donor DNA optimisation to enhance both efficiency and specificity of recombinase-mediated insertions. They demonstrated up to ~53% insertion efficiency and ~97% genome-wide specificity in human cells with engineered variants - making site-specific insertion of large DNA cargo (up to ~12 kb) practical for therapeutic and research applications https://www.nature.com/articles/s41587-025-02895-3

Seamless ESGCT 2024 (found in a PDF on their site): Highlights

P0670 - Reprogramming Large Serine Recombinases (LSRs) for Site-Specific Integration

Key Points:

Seamless uses a proprietary search motif to identify target sites in almost all coding genes and human safe harbour sites, giving broad applicability beyond sequences similar to natural recombinase targets.

Through directed evolution and rational design, they engineered LSRs to target four selected sites in the human genome.

Engineered LSR clones showed high activity in bacteria, which translated well to human cells.

A leading engineered enzyme, IntSTX-SH2, could precisely integrate DNA into the SH2 locus in human cells.

Optimisation to IntSTX-SH2 2.0 produced a three-fold activity improvement over the first generation, with room for further enhancement.

P0590 - Zinc-Finger Dependent Recombinases (ZFD-Conditional Editing)

Key Points:

Seamless combined Zinc-Finger Binding Domains (ZFDs) with tyrosine recombinases (Y-SSRs) and LSRs.

Engineered variants were inactive without the correct ZFD target site and reactivated only when the site was present, ensuring high specificity.

This strategy increases efficiency and precision of recombinases.

Expands the suite of DNA editing techniques, giving the ability to program edits in a conditional, highly controlled manner.

So Seamless is moving beyond traditional recombinase limits by searching almost all genes for editable sites, programming LSRs to target chosen human sequences, enhancing efficiency via iterations (like IntSTX-SH2 2.0), and increasing specificity with zinc-finger conditional activation.

This positions Seamless with a platform capable of safe, precise, and flexible gene integration, competitive with Sangamo’s MINT, but with greater programmability for new target sites and conditional editing capability (via ZFDs).

All this builds directly on the foundational work described in these papers https://www.nature.com/articles/s41587-023-02121-y https://link.springer.com/article/10.1186/s13059-023-03097-3 https://academic.oup.com/nar/article/51/10/5285/7157522

The Basecamp Research platform is called aiPGI and powered by EDEN evolutionary AI models (developed with NVIDIA). It ''learns the language of DNA and patterns of evolution.'' The models generate active insertion proteins tailored to target loci in the human genome using just the target sequence.

So rather than evolving or modifying natural recombinases, Basecamp's EDEN models are trained on massive evolutionary datasets to generate proteins with desired insertion activity. This aims to go beyond optimisation with the AI inventing new sequence solutions for insertion enzymes tailored to specific sites, potentially covering a much wider landscape of targets compared to manually (with directed evolution, rational design of recombinases, and/or protein engineering) evolved recombinases.

Editas are leveraging metagenomic mining, LSR bioinformatics, and high-throughput screening. They have identified a large library of candidate enzymes capable of overcoming the size, specificity, and repair-dependency limitations of current genome editing technologies.

This is conceptually similar to what Seamless and Sangamo are doing, but Editas emphasises large-scale discovery from metagenomic diversity and functional screening in human cells as the core of their platform.

https://www.editasmedicine.com/wp-content/uploads/2024/05/ASGCT-LSR-Poster.pdf

They got a few thing wrong, like the partnerships.

Well , THAT's a kick in the nutz ...

$0.55+

$SGMO 💹

Why Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Up 16.46%

Jan 29, 2026

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Sangamo Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Sangamo Therapeutics, Inc.’s stock price such as:
• Sangamo Therapeutics, Inc.’s current stock price and volume
• Why Sangamo Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for SGMO from analysts
• SGMO’s stock price momentum as measured by its relative strength

About Sangamo Therapeutics, Inc. (SGMO)
Before we jump into Sangamo Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Sangamo Therapeutics, Inc.’s Stock Price as of Market Close
As of January 29, 2026, 12:33 PM, CST, Sangamo Therapeutics, Inc.’s stock price was $0.480.

Sangamo Therapeutics, Inc. is up 31.88% from its previous closing price of $0.364.

During the last market session, Sangamo Therapeutics, Inc.’s stock traded between $0.400 and $0.480. Currently, there are approximately 304.27 million shares outstanding for Sangamo Therapeutics, Inc..

Sangamo Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Sangamo Therapeutics, Inc. Stock Price History
Sangamo Therapeutics, Inc.’s (SGMO) price is currently up 14.26% so far this month.

During the month of January, Sangamo Therapeutics, Inc.’s stock price has reached a high of $0.480 and a low of $0.355.

Over the last year, Sangamo Therapeutics, Inc. has hit prices as high as $1.400 and as low as $0.355. Year to date, Sangamo Therapeutics, Inc.’s stock is up 14.26%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Sangamo Therapeutics, Inc. Stock’s Price to Rise?
Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 28, 2026, there were 0 analysts who downgraded Sangamo Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Sangamo Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Sangamo Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Sangamo Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Sangamo Therapeutics, Inc. (SGMO) by visiting AAII Stock Evaluator.

Relative Price Strength of Sangamo Therapeutics, Inc.
Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 28, 2026, Sangamo Therapeutics, Inc. has a weighted four-quarter relative price strength of -28.50%, which translates to a Momentum Score of 6 and is considered to be Very Weak.

Sangamo Therapeutics, Inc. Stock Price: Bottom Line
As of January 29, 2026, Sangamo Therapeutics, Inc.’s stock price is $0.480, which is up 31.88% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Sangamo Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

https://www.aaii.com/investingideas/article/418378-why-sangamo-therapeutics-inc8217s-sgmo-stock-is-up-1646

$SGMO 🗞️

EDIT is actively researching large serine recombinases (LSRs) as part of its platform efforts. In a preclinical presentation at ASGCT '24, they included research on identifying potent LSRs as part of its effort to develop novel technologies https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-present-pre-clinical-data-demonstrating

The goal of this work is to expand the types of edits they can make in vivo, beyond CRISPR nucleases, to include knocking in entire genes - a capability similar in concept to what recombinase platforms like Sangamo's MINT and Seamless aim for.

Other companies, including Basecamp Research, are using AI to learn the rules for how recombinases target different sequences of DNA. Earlier this month, Basecamp announced its AI model could create new recombinases from scratch https://www.prnewswire.co.uk/news-releases/basecamp-research-launches-world-first-ai-models-for-programmable-gene-insertion-302657979.html https://www.biorxiv.org/content/10.64898/2026.01.12.699009v1.full

Seamless also uses AI, but to keep track of which mutations improve or hinder the activity of its enzymes, and feeds those results into a machine learning program that helps it pick out a library of enzymes for its next round of directed evolution. Since Seamless launched in 2023, it has sped up the process of evolving recombinases to target new sites from two years to under six months.

Recombinase tech https://www.fiercebiotech.com/biotech/lilly-pens-11b-pact-german-biotech-work-gene-editing-med-hearing-loss

Rather than relying on one fixed enzyme like Bxb1 (SGMO's MINT platform), Seamless engineers multiple recombinase families, including large serine recombinases and others like Cre, and uses directed evolution plus machine learning (to tailor them to target chosen sequences). This potentially allows the enzymes designed by Seamless to excise, replace, invert, or insert DNA, giving broader (functional) capabilities beyond just integration. The goal is direct, precise gene insertions without the need for genomic landing pads.

Thanks...Late start today...🥳

Going out at .49 tooHigh risk going out of business bankrupt

.44 alert for a quick flip only 

Nice grab...🥳

SGMO................................................https://stockcharts.com/sc3/ui/?s=SGMO&p=W&b=5&g=0&id=p86431144783

.38 going out of business Xmas sale bite a few 

For SGMO to be compliant with the deficiency notice by Oct 23, it means they would need to start trading at $1 or above for ten consecutive trading days before the initial deadline of Oct 23 (which is Oct 9th). For example, if on Oct 10, nine trading days before the deadline, they started trading at or above $1, and stayed there thru Oct 23, they would be considered non-compliant. They would need to ask for an extension, and if granted, they would be given another 180 days to become compliant. They can't ''bank'' the nine consecutive days of trading above $1. Meaning, the first compliance period is over, and a new 180 day compliance period starts with a ''new'' ten trading day trading above $1 requirement to meet compliance.

But in all likelihood they would be granted the new extension. But if Oct 23rd come around and the company is not trading above $1 it's likely because they have bigger problems. Point is they are weeks from insolvency at this point. Something has to happen...!

SGMO took a position in this this week over sold consolidated chart with strong building momentum al TAs crossing pivots moved above the cloud last set up like this took it from here to $3 range

1 year ago today, since I posted here. (Just something I noticed when finding the board in my past.)
Bought .65's yesterday and looking for move back over a $.

SGMO...........................................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783

Thanks...not in right now...🥳

$SGMO on the move ...

SGMO..................................................https://stockcharts.com/h-sc/ui?s=SGMO&p=W&b=5&g=0&id=p86431144783

SGMO...58...🥳...on the Upper Bollie Break...

georgie18

Member Level
Re: georgie18 post# 1012

Tuesday, June 03, 2025 10:47:06 AM

Post#
1017
of 1023
SGMO...5137...🥳...Bullish Psar flip coming off the .45 range bottom...

Partnership news coming next

They have a 30 year history of failures and pivots. Also, PFE, GILD, SNY, NVS and BIIB all ditched the partnerships with them. Fabry seems to be the last chance to prove that they can actually complete and deliver a therapy. Everything else is (mostly) talk.